Surgical trauma: hyperinflammation versus immunosuppression?
- 28 May 2004
- journal article
- review article
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 389 (6) , 475-484
Abstract
Experimental and clinical studies have brought evidence that surgical trauma markedly affects the immune system, including both the specific and the non-specific immune response. This report reviews the present knowledge on the mechanisms of surgical trauma-induced immune dysfunction and outlines experimental and clinical approaches to find effective treatment strategies. Major surgical trauma induces an early hyperinflammatory response, which is characterized by (1) pro-inflammatory tumour necrosis factor alpha (TNF), interleukin (IL)-1, and IL-6 cytokine release and (2) neutrophil activation and microvascular adherence, as well as (3) uncontrolled polymorphonuclear (PMN) and macrophage oxidative burst. The massive and continuous IL-6 release induces an acute phase response, but, more importantly, also accounts for the up-regulation of major anti-inflammatory mediators, such as prostaglandin (PG) E2, IL-10 and transforming growth factor (TGF)-ß. This results in surgical, trauma-induced, immunosuppression, as indicated by (1) monocyte deactivation, reflected by the lack of monocytic TNF- production upon lipopolysaccharide (LPS) stimulation, and (2) a shift of the Th1/Th2 ratio towards a Th2-dominated cytokine pattern. The imbalance between pro-inflammatory and anti-inflammatory cytokines and immuno-competent cells determines the phenotype of disease and should help the physician to compose the therapeutic strategy. In fact, recent clinical studies have shown that both the initial uncontrolled hyperinflammation and the continued cell-mediated immunosuppression represent primary targets to counteract post-surgery immune dysfunction. The balance between inflammatory and anti-inflammatory forces may be restored by interferon gamma (IFN-γ) to counteract monocyte deactivation; the anti-inflammatory PGE2 may be inhibited by indomethacin to attenuate immunosuppression; or the initial hyperinflammation may be targeted by administration of anti-inflammatory substances, such as granulocyte colony-stimulating factor (G-CSF), hydoxyethyl starch, or pentoxifylline. When drawing up the therapeutic regimen the physician should not consider hyperinflammation versus immunosuppression, but hyperinflammation and immunosuppression, aiming at restoring an appropriate mediator- and immune cell-associated balance.Keywords
This publication has 110 references indexed in Scilit:
- Increased rates of pulmonary metastases following sham laparotomy compared to CO2 pneumoperitoneum and the inhibition of metastases utilizing perioperative immunomodulation and a tumor vaccineSurgical Endoscopy, 2002
- The influence of CO2 versus helium insufflation or the abdominal wall lifting technique on the systemic immune responseSurgical Endoscopy, 2001
- Local Inflammatory Peritoneal Response to Operative Trauma: Studies on Cell Activity, Cytokine Expression, and Adhesion MoleculesThe European Journal of Surgery, 1999
- Immunomodulatory Aspects of TransfusionAnesthesiology, 1999
- Laparotomy and laparoscopy differentially accelerate experimental flank tumour growthBritish Journal of Surgery, 1998
- IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses.Journal of Clinical Investigation, 1998
- Monocyte deactivation-rationale for a new therapeutic strategy in sepsisIntensive Care Medicine, 1996
- Release of Anti-inflammatory Mediators after Mechanical Trauma Correlates with Severity of Injury and Clinical OutcomeThe Journal of Trauma: Injury, Infection, and Critical Care, 1995
- The acute phase responseImmunology Today, 1994
- InterleukinsClinical Pharmacokinetics, 1991